JP2002501526A - 乳汁における免疫グロブリンａの生成方法 - Google Patents

乳汁における免疫グロブリンａの生成方法

Info

Publication number
JP2002501526A
JP2002501526A JP50054699A JP50054699A JP2002501526A JP 2002501526 A JP2002501526 A JP 2002501526A JP 50054699 A JP50054699 A JP 50054699A JP 50054699 A JP50054699 A JP 50054699A JP 2002501526 A JP2002501526 A JP 2002501526A
Authority
JP
Japan
Prior art keywords
iga
antigen
milk
imm
immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP50054699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002501526A5 (OSRAM
Inventor
ジョイ ホッドキンソン，アリソン
チャールズ ホッドキンソン，スティーブン
Original Assignee
アグリサーチ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アグリサーチ リミティド filed Critical アグリサーチ リミティド
Publication of JP2002501526A publication Critical patent/JP2002501526A/ja
Publication of JP2002501526A5 publication Critical patent/JP2002501526A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP50054699A 1997-05-29 1998-05-29 乳汁における免疫グロブリンａの生成方法 Ceased JP2002501526A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ31495997 1997-05-29
NZ314959 1997-05-29
PCT/NZ1998/000070 WO1998054226A1 (en) 1997-05-29 1998-05-29 Processes for production of immunoglobulin a in milk

Publications (2)

Publication Number Publication Date
JP2002501526A true JP2002501526A (ja) 2002-01-15
JP2002501526A5 JP2002501526A5 (OSRAM) 2005-12-08

Family

ID=19926267

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50054699A Ceased JP2002501526A (ja) 1997-05-29 1998-05-29 乳汁における免疫グロブリンａの生成方法

Country Status (9)

Country Link
US (3) US6616927B2 (OSRAM)
EP (1) EP0990001B1 (OSRAM)
JP (1) JP2002501526A (OSRAM)
AT (1) ATE325817T1 (OSRAM)
AU (1) AU738888B2 (OSRAM)
BR (1) BR9809186A (OSRAM)
CA (1) CA2291487A1 (OSRAM)
DE (1) DE69834490T2 (OSRAM)
WO (1) WO1998054226A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012250984A (ja) * 2005-10-21 2012-12-20 Gtc Biotherapeutics Inc 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ285883B6 (cs) * 1998-01-19 1999-11-17 Medipharm Cz, S. R. O. Perorální přípravek k prevenci a léčbě infekčních gastroenteritid telat
US20020009429A1 (en) * 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
KR100627635B1 (ko) * 1999-11-01 2006-09-25 뮤코 박스 홀딩 비.브이. 가축에서 유선 분비 항체를 제조하는 방법
US7074454B1 (en) 1999-11-01 2006-07-11 Mucovax Holding B.V. Production of mammary secretion antibodies in farm animals
US6974573B2 (en) 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
AU2002239159A1 (en) * 2001-03-12 2002-09-24 Rijksuniversiteit Groningen Modulation of a balance between the gut mucosal immune system and the intestinal microflora
AU2002367161A1 (en) * 2001-12-24 2003-07-15 Fonterra Co-Operative Group Limited Immunoglobulin composition
EP1673087B1 (en) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
FI116904B (fi) * 2003-10-21 2006-03-31 Suomen Rehu Oy Menetelmä maidon koostumuksen muuttamiseksi ja maidon käyttö
WO2005041992A2 (en) * 2003-10-22 2005-05-12 Harry Leneau Colostrum compositions and methods
FR2861306B1 (fr) * 2003-10-28 2008-07-04 Vivafeed Utilisation du shiitake pour augmenter le taux d'immunoglobulines laitieres
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
NZ530709A (en) * 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
JP2008526757A (ja) * 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤製剤および方法
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
AU2006246299B2 (en) * 2005-05-10 2013-10-24 Saputo Dairy Australia Pty Limited Immunoglobulin fraction and process therefor
EP2222192A1 (en) * 2007-12-11 2010-09-01 Nestec S.A. Prevention and treatment of otitis media using iga enriched milk
EP2138187A1 (en) * 2008-06-24 2009-12-30 Nestec S.A. Probiotics, secretory IgA and infection
WO2010050829A1 (en) * 2008-10-31 2010-05-06 Vialactia Biosciences (Nz) Limited Marker assisted selection of a mammalian subject for desired immunoglobulin phenotype
ES2742734T3 (es) 2010-11-23 2020-02-17 Pantheryx Inc Composiciones y procedimientos para el tratamiento en aplicaciones clínicas de espectro general, no diferenciadas o mixtas
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
AU2014217561B2 (en) 2013-02-13 2018-11-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-TNF-alpha antibodies and uses thereof
WO2020176637A1 (en) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH627079A5 (en) 1977-04-15 1981-12-31 Nestle Sa Process for preparing a protein concentrate containing immunological factors of milk origin
US4229342A (en) 1977-05-18 1980-10-21 Rhone-Poulenc Industries Process for extracting proteins from milk using silica and anion exchange resins
FR2520235A1 (fr) 1982-01-27 1983-07-29 Bel Fromageries Procede de separation d'immunoglobulines a partir de colostrum
US4971794A (en) * 1982-09-02 1990-11-20 Unilever Patent Holdings B.V. Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili
DE3432718C1 (de) 1984-09-06 1986-05-22 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen
US5066491A (en) 1985-04-15 1991-11-19 Protein Technology, Inc. Method of disease treatment utilizing an immunologically active whey fraction
FR2584727B1 (fr) 1985-07-11 1988-06-17 Roussel Uclaf Procede d'extraction de proteines du lait, produits, application du procede, et compositions pharmaceutiques
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
GB8729031D0 (en) 1987-12-11 1988-01-27 Express Foods Group Ltd Isolation of immunoglobulin rich fraction from whey
US5001230A (en) * 1988-02-18 1991-03-19 Schering Corporation T cell activation markers
US5258178A (en) 1990-07-30 1993-11-02 Abbott Laboratories Method and product for the treatment of gastric disease
IE76730B1 (en) 1990-07-30 1997-11-05 Abbott Laboraties Method and product for the treatment of gastric disease
NZ239466A (en) 1990-08-17 1993-12-23 Us Agriculture Desalted colostrum: spray dried product from retentate of
US5418137A (en) * 1991-09-26 1995-05-23 Paravax, Inc. Flea membrane binding site proteins as screening tools
US5155213A (en) * 1991-10-28 1992-10-13 Eloy Padron Method for isolating IgAs in the feces
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
CA2242931A1 (en) 1996-01-31 1997-08-07 David Francis Elgar Production of an immunoglobulin enriched fraction from whey protein solutions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012250984A (ja) * 2005-10-21 2012-12-20 Gtc Biotherapeutics Inc 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法

Also Published As

Publication number Publication date
WO1998054226A1 (en) 1998-12-03
DE69834490D1 (de) 2006-06-14
EP0990001A4 (en) 2004-08-25
CA2291487A1 (en) 1998-12-03
BR9809186A (pt) 2000-08-01
EP0990001A1 (en) 2000-04-05
US20030103989A1 (en) 2003-06-05
US20020076410A1 (en) 2002-06-20
ATE325817T1 (de) 2006-06-15
US6616927B2 (en) 2003-09-09
AU7942098A (en) 1998-12-30
EP0990001B1 (en) 2006-05-10
DE69834490T2 (de) 2007-03-01
AU738888B2 (en) 2001-09-27
US20030074676A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
EP0990001B1 (en) Processes for production of immunoglobulin a in milk
CA2260007C (en) Method for treating gastrointestinal damage
US5585098A (en) Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
US5017372A (en) Method of producing antibody-fortified dry whey
JPH08231425A (ja) トリの抗体を用いた哺乳動物の受動免疫化
WO1997020577A1 (en) Improved therapeutic formulation and method
US20070141079A1 (en) Antibody production in farm animals
US20020009429A1 (en) Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
US4971794A (en) Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili
JPS62215534A (ja) 鶏卵からの特異的抗体含有材料およびその製造方法と用途
EP0484148A1 (en) A method for producing a new medicine for both treating and preventing peptic ulcer diseases and gastritis and thus formulated medicines
JPH02160726A (ja) ワクチン
WO1999002188A1 (en) Hen egg yolk antibodies to clostridium difficile antigens and use in therapy for pseudomembranous colitis
CA2233935A1 (en) Process for isolating immunoglobulins in whey
Xu et al. Bovine immune colostrum against 17 strains of diarrhea bacteria and in vitro and in vivo effects of its specific IgG
JPH04275232A (ja) 胃炎，胃または十二指腸潰瘍予防食品
RU2062109C1 (ru) Способ получения иммунного препарата
WO2005070458A1 (en) Improved iga production method
KR100627635B1 (ko) 가축에서 유선 분비 항체를 제조하는 방법
NZ501247A (en) Processes for production of immunoglobulin A in milk comprising inducing IgA via active immunisation with intramammary, intraperitoneal and intramuscular administration.
US20170056497A1 (en) Method of Treating Protozoal Gastrointestinal Disorders in Immunocompromised Patients
MXPA99010944A (en) Processes for production of immunoglobulin a in milk
JPH05306238A (ja) 特異的抗体及びカイコ感染症防除組成物
JP2001011094A (ja) 乳ホエ−タンパク中の生理活性物質およびその製造法ならびにその使用法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080520

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20081014

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081202